Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Purification of VSV-G Pseudotyped Lentivirus for Stem Cell Transduction

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Purification of VSV-G Pseudotyped Lentivirus for Stem Cell Transduction

CELL & GENE | RNA | BIOLOGICS

Purification Strategies for Clinical-Grade Lentiviral Vectors.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Executive Summary

The purification of VSV-G pseudotyped lentiviral vectors for transducing sensitive cell populations, such as hematopoietic stem cells (HSCs), presents distinct process challenges. Standard protocols can fail to adequately remove contaminants like host cell proteins and plasmid DNA, which may compromise transduction efficiency and introduce variability. A tailored purification strategy is required to achieve the high purity necessary for clinical-grade applications while preserving vector infectivity and function.

Technical FAQ

    What is the primary challenge with VSV-G pseudotyped lentivirus?

    The broad tropism conferred by the Vesicular Stomatitis Virus Glycoprotein (VSV-G) envelope makes it effective for transducing many cell types. This same envelope protein can be sensitive to purification conditions, and the vector itself is susceptible to inactivation by serum components, a factor that must be addressed for in vivo applications.

    What is the requirement for high purity in stem cell transduction?

    Stem cell populations, particularly HSCs, are sensitive to impurities. Residual host cell proteins, DNA, and other process-related contaminants can negatively impact cell viability, differentiation potential, and overall transduction outcomes. Achieving high purity minimizes these confounding variables.

    How does purification impact vector stability?

    The purification process must balance contaminant removal with the preservation of vector integrity. Aggressive methods can damage the viral envelope, reducing infectivity. Research into vector modifications, such as PEGylation, has demonstrated that protecting the vector from serum components can improve stability and subsequent in vivo performance (PMID: 14694122). This principle informs the development of gentle yet effective purification workflows.

Tailored Purification for High-Titer Lentiviral Vectors

A standardized template for lentiviral vector purification does not exist. The optimal strategy is dictated by the specific application, scale, and target cell type. For ex vivo transduction of HSCs, the process must be designed to yield a highly concentrated, pure vector preparation with minimal loss of functional titer.

Our approach involves a multi-step chromatographic process designed to separate intact viral particles from process-related impurities. This method is more scalable and reproducible than traditional ultracentrifugation techniques, providing a clearer path from research-grade to GxP-compliant manufacturing.

Key process considerations include:

  • Clarification: Initial removal of cells and large debris post-harvest without compromising vector integrity.

  • Chromatography: Utilization of affinity or ion-exchange chromatography to capture the vector and remove soluble contaminants.

  • Polishing Steps: Further purification using techniques like size exclusion chromatography to achieve the final desired purity profile.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Strategic Vector Design and Envelope Selection

While VSV-G is a common choice, the selection of the envelope protein is a strategic decision made upstream of manufacturing. Different pseudotypes can confer distinct transduction patterns, which may be advantageous for specific therapeutic goals. For instance, studies comparing various envelope proteins have shown that alternatives to VSV-G can yield efficient and stable transduction in specific tissues (PMID: 11991743). This highlights the importance of aligning vector design with the intended biological outcome before initiating production and purification.

Our >100,000 sq ft facility and experienced team support an 18-24 month timeline to get candidates to IND, built on a foundation of robust process development. While the Franklin Biolabs brand launched in 2024, our team’s work has contributed to a 100% successful IND rate for sponsors since 2019.

From Research to IND-Enabling Production

Franklin Biolabs provides research-grade lentiviral vectors produced with the same scientific rigor applied to our GxP-compliant manufacturing programs. This ensures that vectors used in early discovery and preclinical validation are representative of what can be produced at a larger scale for IND-enabling toxicology studies, minimizing risks during program advancement.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Technical Visualization: Lentiviral Vector Purification Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities